Journals / Solunum / 2012 / Cilt: 14 - Sayı: 2

Inhaled therapy in children

Çocuklarda inhaler tedavi uygulamaları

Journal
Solunum
Pages
63–72
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The most efficient method of delivering aerosol to children depends on the age and clinical condition of the child.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aerosol medications are replacing oral and injected drugs that are used in the treatment of respiratory and other diseases.
📊
Key Findings & Data:They include antibiotics, mucolytics, short and long–acting bronchodilators, anticholinergics, steroidal antiinflamatory drugs, non-steroidal antiinflamatory drugs.
💡
Conclusion & Impact:The most efficient method of delivering aerosol to children depends on the age and clinical condition of the child.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aerosol medications are replacing oral and injected drugs that are used in the treatment of respiratory and other diseases. There are many advantages of aerosolized drug delivery to the lung. This route of administration is non-invasive, provides a faster onset of action for some drugs compared to oral therapy, avoiding the side-effects associated with oral and injection therapy and the pain associated with injection therapy. Many therapeutic drugs are being administered to the lung by aerosols. They include antibiotics, mucolytics, short and long–acting bronchodilators, anticholinergics, steroidal antiinflamatory drugs, non-steroidal antiinflamatory drugs. Many new devices are now available for delivering aerosolized medications. The current methods to deliver therapeutic aerosols can be classified in three categories: nebulizers, pressurized metered dose inhalers (pMDI’s) and dry powder inhalers (DPT’s). Various types of inhalers have become available in our country. The most efficient method of delivering aerosol to children depends on the age and clinical condition of the child.

Özet

Aerosol ilaçlar, solunum yolu hastalıklarının ve sistemik hastalıkların tedavisinde kullanılan oral veya parenteral uygulanan ilaçların yerini almaya başlamaktadır. Aerosol yolla ilaç uygulamasının başlıca avantajları, noninvazif olması, oral tedavi ile karşılaştırıldığında etkinin daha hızlı başlaması, oral ve enjeksiyon tedavisine göre yan etkilerinin daha az olması ve enjeksiyona bağlı ağrının oluşmamasıdır. Aerosol yolla akciğerlere uygulanabilen terapötik ilaçlar arasında antibiyotikler, mukolitikler, kısa ve uzun etkili bronkodilatörler, antikolinerjikler, steroid ve nonsteroid antiinflamatuar ilaçlar sayılabilir. Günümüzde, aerolize ilaç uygulaması amacıyla kullanımda olan araçlar üç kategoride sınıflandırılabilir: nebülizerler, ölçülü doz inhalerler (ÖDİ) ve kuru toz inhalerler (KTİ). Ülkemizde de çeşitli tipte inhaler ilaçlar bulunmaktadır. Çocuklarda en etkili inhalasyon yönteminin seçimi, çocuğun yaşına ve klinik durumuna bağlıdır. Seçilen uygun yönteme göre çocukların tedaviye uyumu artırılabilmekte ve hastalık seyri olumlu yönde değiştirilebilmektedir.

🔖

Cite This Article

PEKCAN, S. (2012). Inhaled therapy in children. Solunum, Cilt: 14 - Sayı: 2, 63–72. https://ajindex.com/articles/314334

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Muers MF. The rational use of nebulizers in clinical practice. Eur Respir Rev 1997;7;189-197
  2. British Thoracic Society Nebulizer Project Group. Current best practice for nebuliser treatment. Thorax 1997;52(Suppl 2):S1-S3
  3. Muers MF. Overview of nebulizer treatment. Thorax 1997;52(Supp 2):25-30
  4. Sly PD, LeSouef PN. Inhaled therapy in paediatrics. J Paediatr Child Health 1991;27:7-10
  5. Guidelines prepared by a European Respiratory Society Task Force on the use of nebulizers: Boe J, Dennis JH, O'Driscoll BR, Bauer TT, Carone M, Dautzenberg B, et al. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J 2001;18:228-242
  6. Janssens HM, Tiddens HA. Aerosol therapy: the special needs of young children. Paediatr Respir Rev 2006;7:S83-S35
  7. Everard ML Aerosol delivery to children. Pediatr Ann 2006;35:630- 636
  8. Dolovich MA, MacIntyre NR, Anderson PJ, Camargo CA Jr, Chew N, Cole CH, et al. Consensus statement: aerosols and delivery devices. American Association for Respiratory Care 2000;45:589-596
  9. Rubin BK. Nebulizer therapy for children: the device-patient interface. Respir Care 2002;47:1314-1319
  10. Dolovich M. Device Selection and outcomes of aerosol therapy: evidence based quidelines. Chest 2005;127:335-371
  11. Chua HL, Collis GG, Newbury AM, Chan K, Bower GD, Sly PD, et al. The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J 1994; 7:2185-2191
  12. Laube BL, Swift DL, Wagner HN Jr, Norman PS, Adams GK 3rd. The effect ofbronchial abstruction on central airways deposition of saline aerosol in patients with asthma. Am Rev Respir Dis 1986;133:740- 743
  13. Newman SP, Pavia D, Clarke SW. Improving the bronchial deposition of pressurized aerosols. Chest 1981;80(6 Suppl):909-911
  14. Laube BL. In vivo measurements of aerosol dose and distrubition: clinical relevance. J Aerosol Med 1996;9(Suppl 1):S77-S91
  15. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination. Respiratory Care 2005;50:1162-1176
  16. Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, et al. Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Patient Clin Microbiol Infect 2005;11:690-703
  17. Frederiksen B, Lanng S, Koch C, Høiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results